
KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma
The anti-CD19/CD20 CAR T-cell therapy KITE-363 showcased high response rates with a manageable safety profile in patients with relapsed/refractory B-cell lymphoma, according to results from a first-in-human phase 1 study (NCT04989803) presented …